Abstract
The COVID-19 pandemic has jolted the health system globally and a paucity of specific drugs and/or vaccine hesitancy led clinicians to indiscriminately use antibiotics. Furthermore, during the early waves of the COVID-19 pandemic, several studies showcased the anti-SARS-CoV-2 efficacy of few antibiotics which further catapulted the idea of using them after emergency approval by the Food and Drug Authority (FDA). This nonjudicial use of antibiotics has unfortunately led to the evolution of antimicrobial resistance (AMR) as a silent pandemic. In this chapter, we describe the previous and recent studies highlighting several antibiotics that are either predicted to target the SARS-CoV-2 virus and/or shown to have efficacy in managing patients with COVID-19. We also discussed the negative implication of antibiotics during COVID-19 and why proper genomic surveillance is required to mitigate the development of AMR in the present and future pandemics.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
